RADX Stock Summary and Trading Ideas (Radiopharm Theranostics Limited - American Depositary Shares | NASDAQ:RADX)

Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.

Radiopharm Theranostics Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol RADX.

As of April 17, 2026, RADX stock price declined to $4.58 with 32,282 million shares trading.

RADX has a beta of -0.43, meaning it tends to be less sensitive to market movements. RADX has a correlation of 0.01 to the broad based SPY ETF.

RADX has a market cap of $35.63 million. This is considered a Sub-Micro Cap stock.

RADX has underperformed the market in the last year with a price return of +6.5% while the SPY ETF gained +36.3%. RADX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -10.9% and +4.1%, respectively, while the SPY returned +2.9% and +8.3%, respectively.

RADX support price is $4.40 and resistance is $4.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RADX shares will trade within this expected range on the day.